On October 8, the Congressional Budget Office (CBO) released a report on the potential federal cost if Medicare decides to cover anti-obesity medications (AOMs) for weight loss, including the much-discussed class of glucagon-like peptide 1s (GLP-1s)
Medicare Part D Gross Spending on GLP-1s Increased Five-Fold Between 2019 and 2024, But Estimated Rebates of Around 50% Mean That Net Spending is Much Lower Gross Medicare Part D spending on GLP-1s in 2024 (not accounting for rebates) totaled $27.5 billion, a five-fold increase from 2019, reflecting an expansion in use of GLP-1s with more recent FDA approvals for type 2 diabetes
After RNA fragmentation, following the standard protocol of the Magna Methylated RNA Immunoprecipitation m6A Kit (Merck Millipore, Germany), immunoprecipitation was performed using m6A antibody
Digestive enzymes break the tripeptide into its individual amino acids before it can enter systemic circulation intact
Narrative Review of Data Supporting Alternate First-Line Therapies Over Metformin in Type 2 Diabetes
It is important to rotate the injection site each week to reduce the risk of irritation
